Cost-of-Illness Studies: An Updated Review of Current Methods

PharmacoEconomics

Volumn 34, Issue 1, 2016, Pages 43-58

  Onukwugha, Eberechukwu ^a   McRae, Jacquelyn ^b   Kravetz, Alex ^a   Varga, Stefan ^c   Khairnar, Rahul ^a   Mullins, C Daniel ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b MERCER UNIVERSITY   (United States)

^c NOTRE DAME OF MARYLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASIA; AUSTRALIA; CAREGIVER; COST OF ILLNESS; EMBASE; EUROPE; HEALTH CARE; HUMAN; MEDLINE; NORTH AMERICA; PRIORITY JOURNAL; SCOPUS; SOUTH AMERICA; SYSTEMATIC REVIEW; HEALTH CARE COST; STATISTICS AND NUMERICAL DATA;

HEALTH CARE COSTS; HUMANS;

EID: 84942017321     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-015-0325-4     Document Type: Article

References (25)

1. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy. 2006;77(1):51–63.
2. Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. Pharmacoeconomics. 2006;24(9):869–90.
3. Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653–71.
4. Mauskopf J, Mucha L. A review of the methods used to estimate the cost of Alzheimer’s disease in the United States. Am J Alzheimers Dis Other Dement. 2011;26(4):298–309.
5. Dee A, Kearns K, O’Neill C, Sharp L, Staines A, O’Dwyer V, et al. The direct and indirect costs of both overweight and obesity: a systematic review. BMC Res Notes. 2014;7:242.
6. Ettaro L, Songer TJ, Zhang P, Engelgau MM. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics. 2004;22(3):149–64.
7. Molinier L, Bauvin E, Combescure C, Castelli C, Rebillard X, Soulie M, et al. Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health. 2008;11(5):878–85.
8. Molinier L, Combescure C, Chouaid C, Daures JP, Housset B, Fabre D, et al. Cost of lung cancer: a methodological review. Pharmacoeconomics. 2006;24(7):651–9.
9. Rice DP. Cost-of-illness studies: fact or fiction? Lancet. 1994;344(8936):1519–20.
10. Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision making. Health Policy. 1987;8(3):317–23.
11. Kymes S. “Can we declare victory and move on?” The case against funding burden-of-disease studies. Pharmacoeconomics. 2014;32(12):1153–5.
12. Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ. 2000;320(7245):1335.
13. Currie G, Kerfoot KD, Donaldson C, Macarthur C. Are cost of injury studies useful? Inj Prev. 2000;6(3):175–6.
14. Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6(3):177–9.
15. Varmus H. Disease-specific estimates of direct and indirect costs of illness and NIH support. Washington, DC: National Institutes of Health; 2000.
16. Pisu M, James N, Sampsel S, Saag KG. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford). 2005;44(6):781–8.
17. Brown P, Ki M, Foxman B. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics. 2005;23(11):1123–42.
18. Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003;111(6):1212–8.
19. Gerber AU, Torre AH, Buscher G, Stock SA, Graf C, Schickendantz S, et al. Direct non-medical and indirect costs for families with children with congenital cardiac defects in Germany: a survey from a university centre. Cardiol Young. 2010;20(2):178–85.
20. Zhou ZY, Koerper MA, Johnson KA, Riske B, Baker JR, Ullman M, et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ. 2015;18(6):457–65.
21. Depont F, Hunsche E, Abouelfath A, Diatta T, Addra I, Grelaud A, et al. Medical and non-medical direct costs of chronic low back pain in patients consulting primary care physicians in France. Fundam Clin Pharmacol. 2010;24(1):101–8.
22. Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood). 2014;33(7):1187–94.
23. Institute of Medicine. Variation in health care spending: target decision making, not geography. Washington, DC: Institute of Medicine; 2013.
24. Gawande A. The hot spotters. The New Yorker. New York: Conde Nast; 2011.
25. Gawande A. The cost conundrum. The New Yorker. New York: Conde Nast; 2009.